1834 Investment Advisors Co. Has $7.21 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Key Points

• 1834 Investment Advisors Co. reduced its holdings in Johnson & Johnson by 4.9%, selling 2,256 shares and ending with a total of 43,482 shares valued at $7.21 million.
• Several institutional investors significantly increased their stakes in Johnson & Johnson, including GAMMA Investing LLC, which boosted its ownership by 24,450.4% during the same quarter.
• Johnson & Johnson recently reported a quarterly earnings per share of $2.77, exceeding analyst expectations, and announced a dividend of $1.30 per share, with a payout ratio of 55.61%.

1834 Investment Advisors Co. reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,482 shares of the company's stock after selling 2,256 shares during the quarter. 1834 Investment Advisors Co.'s holdings in Johnson & Johnson were worth $7,211,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company's stock worth $38,800,371,000 after purchasing an additional 1,170,120 shares in the last quarter. Northern Trust Corp boosted its position in shares of Johnson & Johnson by 12.3% during the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after acquiring an additional 3,363,235 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Johnson & Johnson by 3.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company's stock valued at $3,133,602,000 after purchasing an additional 712,181 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Johnson & Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company's stock valued at $3,031,955,000 after purchasing an additional 448,666 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on JNJ shares. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Trading Up 1.1%

JNJ traded up $1.87 during midday trading on Friday, hitting $173.40. 7,686,049 shares of the company were exchanged, compared to its average volume of 9,496,232. The firm has a market capitalization of $417.61 billion, a P/E ratio of 18.55, a P/E/G ratio of 2.18 and a beta of 0.41. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $173.96. The firm's 50 day moving average price is $159.26 and its 200-day moving average price is $157.44. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.82 earnings per share. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. Johnson & Johnson's payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.